FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1160-1174 March 13, 2008 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Supplementary Material Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Cancer cells may acquire the capacity for autonomous and dysregulated proliferation through the uncontrolled production of specific molecules that promote cell growth (growth factors) or through abnormal, enhanced expression of specific proteins (growth factor receptors) on the cell membranes to which growth factors selectively bind. Both processes trigger a series of intracellular signals that ultimately lead to the proliferation of cancer cells, induction of angiogenesis, and metastasis.¹ The majority of human epithelial cancers are marked by functional activation of growth factors and receptors of the epidermal growth factor receptor (EGFR) family. Given this phenomenon, EGFR was the first growth factor . . . [Full Text of this Article]

EGFR in Human Carcinogenesis

Development of EGFR Antagonists for Anticancer Therapy

Clinical Efficacy of EGFR Antagonists in Human Cancers

Non–Small-Cell Lung Cancer

Colorectal Cancer

Squamous-Cell Carcinoma of the Head and Neck

Pancreatic Cancer

Predicting the Response to Anti-EGFR Drugs

Clinical and Pathological Predictors

EGFR Protein Expression

Somatic EGFR Gene Mutations

Increased EGFR Copy Number

Resistance to EGFR Antagonists

Intrinsic Resistance

Acquired Resistance

Future Directions

Source Information

From the Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F. Magrassi and A. Lanzara, Second University of Naples (F.C.); and the Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II (G.T.) — both in Naples, Italy.

Address reprint requests to Dr. Ciardiello at the Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F. Magrassi and A. Lanzara, Second University of Naples, Via S. Pansini 5, 80131 Naples, Italy, or at fortunato.ciardiello@unina2.it.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.